HIF-1α confers resistance to induced stress in bone marrow-derived mesenchymal stem cells

Archives of Medical Research

Volumn 44, Issue 3, 2013, Pages 185-193

  Kiani, Ali Asghar ^a   Kazemi, Ahmad ^a   Halabian, Rahele ^b   Mohammadipour, Mahshid ^c   Jahanian Najafabadi, Ali ^d   Roudkenar, Mehryar Habibi ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; HIF 1 ; HIF 1 siRNA; Mesenchymal stem cells; Oxidative stress

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DEATH; CELL EXPANSION; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION;

APOPTOSIS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL HYPOXIA; CELL SURVIVAL; CLONING, MOLECULAR; HUMANS; HYDROGEN PEROXIDE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MESENCHYMAL STROMAL CELLS; OXIDATIVE STRESS; RNA, SMALL INTERFERING; SERUM; UP-REGULATION;

EID: 84876860824     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.03.006     Document Type: Article

References (34)

1. Marion N.W., Mao J.J. Mesenchymal stem cells and tissue engineering. Methods Enzymol 2006, 420:339-361.
2. Barry F.P., Murphy J.M. Mesenchymalstem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004, 36:568-584.
3. Horwitz E., Gordon P., Koo W. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002, 99:8932-8937.
4. Sotiropoulou P., Perez S., Salagianni M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stemcells. Stem Cells 2006, 24:462-471.
5. Koç O.N., Day J., Nieder M. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transpl 2002, 30:215-222.
6. Le Blanc K., Rasmusson I., Sundberg B. Treatment of severe acute graft-vs.-host disease with third-party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
7. Le Blanc K., Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 2005, 11:321-334.
8. Jiang Y., Jahagirdar B.N., Reinhardt R.L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
9. Barry F.P., Murphy J.M., English K., et al. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev 2005, 14:252-265.
10. Pal R., Hanwate M., Totey S.M. Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow-derived mesenchymal stem cells before transplantation. J Tissue Eng Regener Med 2008, 2:436-444.
11. Ma T., Grayson W.L., Fröhlich M., et al. Hypoxia and stem cell-based engineering of mesenchymal tissues. Biotechnol Prog 2009, 25:32-42.
12. Semenza G.L. Targeting HIF-1 for cancer therapy. Nature Rev Cancer 2003, 3:721-732.
13. Weidemann A., Johnson R. Biology of HIF-1alpha. Cell Death Differ 2008, 15:621-627.
14. Kakinuma Y., Katare R.G., Arikawa M., et al. A HIF-1alpha-related gene involved in cell protection from hypoxia by suppression of mitochondrial function. FEBS Lett 2008, 582:332-340.
15. Halabian R., Mohammadi H.M., Salimimohammad A., et al. Genetically engineered mesenchymal stem cells stably expressing green fluorescent protein. Iranian J Basic Med Sci 2010, 13:24-30.
16. Mohammadzadeh M., Halabian R., Gharehbaghian A., et al. Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity. Cell Stress Chaperones 2012, 17:553-565.
17. Kamiya N., Watanabe H., Habuchi H., et al. Versican/PG-M regulates chondrogenesis as an extracellular matrix molecule crucial for mesenchymal condensation. J Biol Chem 2006, 281:2390-2400.
18. Hamedi-Asl P., Halabian R., Bahmani P., et al. Adenovirus-mediated expression of the HO-1 protein within MSCs decreased cytotoxicity and inhibited apoptosis induced by oxidative stresses. Cell Stress Chaperones 2012, 17:181-190.
19. Raucci M.G., Alvarez-Perez M.A., Demitri C., et al. Proliferation and osteoblastic differentiation of hMSCs on cellulose-based hydrogels. J Appl Biomater Function Mater 2012, 10:302-307.
20. Semenza G.L. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002, 64:993-998.
21. Simsek T., Kocabas F., Zheng J., et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 2010, 7:380-390.
22. Keith B., Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472.
23. Majmundar A.J., Wong W.J., Simon M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010, 40:294-309.
24. Zhu W., Chen J., Cong X., et al. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 2006, 24:416-425.
25. Gui C., Wang J.A., He A.N., et al. Heregulin protects mesenchymal stem cells from serum deprivation and hypoxia-induced apoptosis. Mol Cell Biochem 2007, 305:171-178.
26. Liu X., Jiang J., Gui C., et al. Angiopoietin-1 protects mesenchymal stem cells against serum deprivation and hypoxia-induced apoptosis through the PI3K/Akt pathway1. Acta Pharmacol Sinica 2008, 29:815-822.
27. Nie Y., Han B.M., Liu X.B., et al. Identification of microRNAs involved in hypoxia-and serum deprivation-induced apoptosis in mesenchymal stem cells. Int J Biol Sci 2011, 7:762-768.
28. Schnitzer S., Schmid T., Zhou J., et al. Hypoxia and HIF-1α protect A549 cells from drug-induced apoptosis. Cell Death Different 2006, 13:1611-1613.
29. Abdel-Mageed A.S., Senagore A.J., Pietryga D.W., et al. Intravenous administration of mesenchymal stem cells genetically modified with extracellular superoxide dismutase improves survival in irradiated mice. Blood 2009, 113:1201-1203.
30. Wang X., Zhao T., Huang W., et al. Hsp20 engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells 2009, 27:3021-3031.
31. Li W., Ma N., Ong L.L., et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 2007, 25:2118-2127.
32. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Disc Today 2007, 12:853-859.
33. Onnis B., Rapisarda A., Melillo G. Development of HIF-1α inhibitors for cancer therapy. J Cell Mol Med 2009, 13:2780-2786.
34. Greenberger L.M., Horak I.D., Filpula D., et al. A RNA antagonist of hypoxia-inducible factor-1 alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Therap 2008, 7:3598-3608.